Skip to main content
Cellromax Science Co., Ltd. logo

Cellromax Science Co., Ltd. — Investor Relations & Filings

Ticker · 471820 ISIN · KR7471820001 KO Manufacturing
Open in API
Filings indexed 90 across all filing types
Latest filing 2025-10-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 471820

About Cellromax Science Co., Ltd.

https://www.cellromax.kr/

Cellromax Science Co., Ltd. is a company specializing in the research, development, and manufacturing of health-related products. Its portfolio is centered on three key areas: health functional foods, derma-cosmetics, and over-the-counter (OTC) pharmaceuticals. The company leverages scientific research and high-quality, naturally derived ingredients to create unique and effective products. Its development philosophy emphasizes optimized formulas and specialized prescriptions designed to support consumer health, skin vitality, and overall well-being.

Recent filings

Filing Released Lang Actions
신탁계약에의한취득상황보고서
Major Shareholding Notification Classification · 95% confidence The document is titled '신탁계약등에의한취득상황보고서' which translates to 'Report on Acquisition Status under Trust Contract'. It details the acquisition of shares through a trust contract, including dates, quantities, prices, and the trustee securities company. It also includes information on shareholding changes and trust contract details. The document is a formal report submitted to the financial supervisory authority (금융감독원장 귀하) and focuses on share acquisition via trust contracts rather than general financial results or management changes. This type of report corresponds to notifications about major shareholding or share acquisition activities rather than financial statements or management reports. Given the detailed share acquisition data and the nature of the report, it fits best under the category of Major Shareholding Notification (MRQ). The document length is 3743 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is MRQ with high confidence.
2025-10-10 Korean
[기재정정]현금ㆍ현물배당결정 (분기배당)
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement of a cash (and in-kind) dividend decision, detailing dividend type, per-share amount, total amount, record date, payment date, board approval date, and a correction to the payment date. This matches the definition for Notice of Dividend Amount (DIV).
2025-09-23 Korean
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 62% confidence The document is a material information report (‘주요사항보고서’) filed under Korean capital markets rules announcing the decision by CelloMax Science to acquire shares in another company (share purchase agreement details, external valuation, payment terms, etc.). This constitutes an acquisition transaction – a form of M&A activity – rather than a pure financing update, insider dealing report, share issuance, or dividend notice. It is neither the annual/interim financial report itself nor merely a notice of its publication. Therefore it best fits the M&A Activity category (TAR).
2025-09-23 Korean
현금ㆍ현물배당결정 (분기배당)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Cellomax Science regarding a decision to pay a quarterly cash dividend. It specifies the dividend amount per share, the record date, the payment date, and the total dividend amount. This aligns perfectly with the definition for 'Notice of Dividend Amount'.
2025-09-12 Korean
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Cellromax Science regarding the determination of a record date for quarterly dividend payments. It specifies the record date (2025-09-30) and the purpose (confirming shareholders for quarterly dividends). Since it announces the dividend record date rather than the final dividend amount or payment details, it falls under general regulatory announcements.
2025-09-12 Korean
감자완료
Share Issue/Capital Change Classification · 100% confidence The document is an official notification regarding the completion of a capital reduction (감자완료) for Cellromax Science. It details the number of shares reduced, changes in total issued shares, and capital changes. This falls under capital structure changes, which is best classified as a Share Issue/Capital Change (SHA) filing, as it relates to the modification of the company's equity structure.
2025-09-01 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.